Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2026)

Organogenesis Holdings' Preferred Stock Liabilities history runs 6 years deep, the most recent figure standing at $136.8 million for Q1 2026.

• On a quarterly basis, Preferred Stock Liabilities rose 9.29% year-over-year to $136.8 million in Q1 2026; TTM through Mar 2026 was $136.8 million, a 9.29% increase from a year earlier, with the FY2025 full-year figure at $133.8 million, up 9.29% from the prior year.
• Preferred Stock Liabilities rose to $136.8 million in Q1 2026 per ORGO's latest filing, from $133.8 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $136.8 million in Q1 2026 and bottomed at $122.4 million in Q4 2024.
• The 3-year median for Preferred Stock Liabilities is $129.4 million (2025), against an average of $129.5 million.
• Across the five-year window, Preferred Stock Liabilities rose 9.29% in 2025 and climbed 9.29% in 2026, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $122.4 million in 2024, then climbed by 9.29% to $133.8 million in 2025, then rose by 2.24% to $136.8 million in 2026.
• Per Business Quant, the three latest ORGO Preferred Stock Liabilities figures stand at $136.8 million (Q1 2026), $133.8 million (Q4 2025), and $130.9 million (Q3 2025).